• Home Dutch
  •  EN 
  • Employee login

Former Clinical pharmacology

Print 
  1. Beyer AR, Fasolo B, Phillips LD, de Graeff PA, Hillege HL. Risk perception of prescription drugs: results of a survey among experts in the European regulatory network. Med Decis Making. 2013 May;33(4):579-92.
  2. Bouma HR, Dugbartey GJ, Boerema AS, Talaei F, Herwig A, Goris M, van Buiten A,Strijkstra AM, Carey HV, Henning RH, Kroese FG. Reduction of body temperaturegoverns neutrophil retention in hibernating and nonhibernating animals bymargination. J Leukoc Biol. 2013 Sep;94(3):431-7.
  3. Bouma HR, Henning RH, Kroese FG, Carey HV. Hibernation is associated withdepression of T-cell independent humoral immune responses in the 13-lined ground squirrel. Dev Comp Immunol. 2013 Mar;39(3):154-60.
  4. Bouma HR, Mandl JN, Strijkstra AM, Boerema AS, Kok JW, van Dam A, Ijzerman A, Kroese FG, Henning RH. 5'-AMP impacts lymphocyte recirculation through activationof A2B receptors. J Leukoc Biol. 2013 Jul;94(1):89-98.
  5. Bouma HR, Samarska IV, Schenk M, Dahlem KK, van den Bos H, Brebenel I, Duin M,Houwertjes MC, Loef BG, Mungroop HE, Struys MM, Epema AH, Henning RH. Microarray analysis of gene expression profiles in the rat kidney demonstrates a localinflammatory response induced by cardiopulmonary bypass. Eur J Anaesthesiol. 2013Aug;30(8):492-500.
  6. Coyne DW, Andress DL, Amdahl MJ, Ritz E, de Zeeuw D. Effects of paricalcitolon calcium and phosphate metabolism and markers of bone health in patients withdiabetic nephropathy: results of the VITAL study. Nephrol Dial Transplant. 2013 Sep;28(9):2260-8.
  7. de Vries DE, Lambers Heerspink HJ. Age and sex effects on the single- andmultiple-dose safety and pharmacokinetics of the new rennin inhibitor ACT-178882.Cardiovasc Ther. 2013 Dec;31(6):e86-7.
  8. de Vries ST, Mol PG, de Zeeuw D, Haaijer-Ruskamp FM, Denig P. Development andInitial Validation of a Patient-Reported Adverse Drug Event Questionnaire. DrugSaf. 2013 Apr 4.
  9. de Zeeuw D. The end of dual therapy with renin-angiotensin-aldosterone systemblockade? N Engl J Med. 2013 Nov 14;369(20):1960-2.
  10. de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H,Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ,Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D,Chertow GM; BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes andstage 4 chronic kidney disease. N Engl J Med. 2013 Dec 26;369(26):2492-503.
  11. de Zeeuw D, Akizawa T, Agarwal R, Audhya P, Bakris GL, Chin M, Krauth M,Lambers Heerspink HJ, Meyer CJ, McMurray JJ, Parving HH, Pergola PE, Remuzzi G,Toto RD, Vaziri ND, Wanner C, Warnock DG, Wittes J, Chertow GM. Rationale andtrial design of Bardoxolone Methyl Evaluation in Patients with Chronic KidneyDisease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON). Am JNephrol. 2013;37(3):212-22.
  12. den Hoed M, Eijgelsheim M, Esko T, Brundel BJ, Peal DS, Evans DM, Nolte IM,Segrè AV, Holm H, Handsaker RE, Westra HJ, Johnson T, Isaacs A, Yang J, Lundby A,Zhao JH, Kim YJ, Go MJ, Almgren P, Bochud M, Boucher G, Cornelis MC, GudbjartssonD, Hadley D, van der Harst P, Hayward C, den Heijer M, Igl W, Jackson AU, KutalikZ, Luan J, Kemp JP, Kristiansson K, Ladenvall C, Lorentzon M, Montasser ME,Njajou OT, O'Reilly PF, Padmanabhan S, St Pourcain B, Rankinen T, Salo P, Tanaka T, Timpson NJ, Vitart V, Waite L, Wheeler W, Zhang W, Draisma HH, Feitosa MF,Kerr KF, Lind PA, Mihailov E, Onland-Moret NC, Song C, Weedon MN, Xie W, Yengo L,Absher D, Albert CM, Alonso A, Arking DE, de Bakker PI, Balkau B, Barlassina C,Benaglio P, Bis JC, Bouatia-Naji N, Brage S, Chanock SJ, Chines PS, Chung M,Darbar D, Dina C, Dörr M, Elliott P, Felix SB, Fischer K, Fuchsberger C, de Geus EJ, Goyette P, Gudnason V, Harris TB, Hartikainen AL, Havulinna AS, Heckbert SR, Hicks AA, Hofman A, Holewijn S, Hoogstra-Berends F, Hottenga JJ, Jensen MK,Johansson A, Junttila J, Kääb S, Kanon B, Ketkar S, Khaw KT, Knowles JW, KoonerAS, Kors JA, Kumari M, Milani L, Laiho P, Lakatta EG, Langenberg C, Leusink M,Liu Y, Luben RN, Lunetta KL, Lynch SN, Markus MR, Marques-Vidal P, Mateo Leach I,McArdle WL, McCarroll SA, Medland SE, Miller KA, Montgomery GW, Morrison AC,Müller-Nurasyid M, Navarro P, Nelis M, O'Connell JR, O'Donnell CJ, Ong KK, NewmanAB, Peters A, Polasek O, Pouta A, Pramstaller PP, Psaty BM, Rao DC, Ring SM,Rossin EJ, Rudan D, Sanna S, Scott RA, Sehmi JS, Sharp S, Shin JT, Singleton AB, Smith AV, Soranzo N, Spector TD, Stewart C, Stringham HM, Tarasov KV,Uitterlinden AG, Vandenput L, Hwang SJ, Whitfield JB, Wijmenga C, Wild SH,Willemsen G, Wilson JF, Witteman JC, Wong A, Wong Q, Jamshidi Y, Zitting P, Boer JM, Boomsma DI, Borecki IB, van Duijn CM, Ekelund U, Forouhi NG, Froguel P,Hingorani A, Ingelsson E, Kivimaki M, Kronmal RA, Kuh D, Lind L, Martin NG,Oostra BA, Pedersen NL, Quertermous T, Rotter JI, van der Schouw YT, VerschurenWM, Walker M, Albanes D, Arnar DO, Assimes TL, Bandinelli S, Boehnke M, de BoerRA, Bouchard C, Caulfield WL, Chambers JC, Curhan G, Cusi D, Eriksson J, FerrucciL, van Gilst WH, Glorioso N, de Graaf J, Groop L, Gyllensten U, Hsueh WC, Hu FB, Huikuri HV, Hunter DJ, Iribarren C, Isomaa B, Jarvelin MR, Jula A, Kähönen M,Kiemeney LA, van der Klauw MM, Kooner JS, Kraft P, Iacoviello L, Lehtimäki T,Lokki ML, Mitchell BD, Navis G, Nieminen MS, Ohlsson C, Poulter NR, Qi L,Raitakari OT, Rimm EB, Rioux JD, Rizzi F, Rudan I, Salomaa V, Sever PS, ShieldsDC, Shuldiner AR, Sinisalo J, Stanton AV, Stolk RP, Strachan DP, Tardif JC,Thorsteinsdottir U, Tuomilehto J, van Veldhuisen DJ, Virtamo J, Viikari J,Vollenweider P, Waeber G, Widen E, Cho YS, Olsen JV, Visscher PM, Willer C,Franke L; Global BPgen Consortium; CARDIoGRAM Consortium, Erdmann J, Thompson JR;PR GWAS Consortium, Pfeufer A; QRS GWAS Consortium, Sotoodehnia N; QT-IGCConsortium, Newton-Cheh C; CHARGE-AF Consortium, Ellinor PT, Stricker BH,Metspalu A, Perola M, Beckmann JS, Smith GD, Stefansson K, Wareham NJ, Munroe PB,Sibon OC, Milan DJ, Snieder H, Samani NJ, Loos RJ. Identification of heartrate-associated loci and their effects on cardiac conduction and rhythmdisorders. Nat Genet. 2013 Jun;45(6):621-31.
  13. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, MannJF, Matsushita K, Wen CP. Chronic kidney disease and cardiovascular risk:epidemiology, mechanisms, and prevention. Lancet. 2013 Jul 27;382(9889):339-52.
  14. Hellemons ME, Denig P, de Zeeuw D, Voorham J, Lambers Heerspink HJ. Isalbuminuria screening and treatment optimal in patients with type 2 diabetes inprimary care? Observational data of the GIANTT cohort. Nephrol Dial Transplant.2013 Mar;28(3):706-15.
  15. Hellemons ME, Lambers Heerspink HJ, Gansevoort RT, de Zeeuw D, Bakker SJ.High-sensitivity troponin T predicts worsening of albuminuria in hypertension;results of a nested case-control study with confirmation in diabetes. JHypertens. 2013 Apr;31(4):805-12.
  16. Hoekman J, Scherngell T, Frenken K, Tijssen R. Improving the efficacy of RAAS blockade in patients with chronic kidney disease. Nature Reviews Nephrology. 2013 2(9):112-121.
  17. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin aglucose-regulating drug with diuretic properties in subjects with type 2diabetes. Diabetes ObesMetab. 2013 Sep;15(9):853-62.
  18. Lambers Heerspink HJ, de Zeeuw D. Novel drugs and intervention strategies forthe treatment of chronic kidney disease. Br J ClinPharmacol. 2013Oct;76(4):536-50.
  19. Lambers Heerspink HJ, Chertow GM, Akizawa T, Audhya P, Bakris GL, Goldsberry A, Krauth M, Linde P, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G,Christ-Schmidt H, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, de Zeeuw D.Baseline characteristics in the Bardoxolone methyl EvAluation in patients withChronic kidney disease and type 2 diabetes mellitus: the Occurrence of renaleveNts (BEACON) trial. Nephrol Dial Transplant. 2013 Nov;28(11):2841-50.
  20. Lambers Heerspink HJ, de Zeeuw D. Dual RAAS blockade has dual effects onoutcome. Nat Rev Endocrinol. 2013 May;9(5):261-3.
  21. Lambers Heerspink HJ, de Borst MH, Bakker SJ, Navis GJ. Improving theefficacy of RAAS blockade in patients with chronic kidney disease. Nat RevNephrol. 2013 Feb;9(2):112-21.
  22. Lambers Heerspink HJ. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection. ContribNephrol. 2013;179:7-14.
  23. Massy ZA, de Zeeuw D. LDL cholesterol in CKD--to treat or not to treat?Kidney Int. 2013 Sep;84(3):451-6.
  24. Matsushita K, Ballew SH, Astor BC, Jong PE, Gansevoort RT, Hemmelgarn BR,Levey AS, Levin A, Wen CP, Woodward M, Coresh J; Chronic Kidney Disease PrognosisConsortium. Cohort profile: the Chronic Kidney Disease Prognosis Consortium. Int J Epidemiol. 2013 Dec;42(6):1660-8.
  25. Mazagova M, Buikema H, van Buiten A, Duin M, Goris M, Sandovici M, HenningRH, Deelman LE. Genetic deletion of growth differentiation factor 15 augmentsrenal damage in both type 1 and type 2 models of diabetes. Am J Physiol RenalPhysiol. 2013 Nov 1;305(9):F1249-64.Aug
  26. Mazagova M, Henning RH, Duin M, van Buiten A, Buikema H, Deelman LE.Troubleshooting methods for microarray gene expression analysis in the onset ofdiabetic kidney disease. J PharmacolToxicol Methods. 2013 Mar-Apr;67(2):61-8.
  27. Mazagova M, Buikema H, Landheer SW, Vavrinec P, Buiten Av, Henning RH,Deelman LE. Growth differentiation factor 15 impairs aortic contractile andrelaxing function through altered caveolar signaling of the endothelium. Am JPhysiol Heart Circ Physiol. 2013 Mar 1;304(5):H709-18.
  28. Mirković K, Doorenbos CR, Dam WA, Lambers Heerspink HJ, Slagman MC, Nauta FL,Kramer AB, Gansevoort RT, van den Born J, Navis G, de Borst MH. Urinary vitamin Dbinding protein: a potential novel marker of renal interstitial inflammation and fibrosis. PLoSOne. 2013;8(2):e55887.
  29. Mol PG, Arnardottir AH, Motola D, Vrijlandt PJ, Duijnhoven RG,Haaijer-Ruskamp FM, de Graeff PA, Denig P, Straus SM. Post-approval safety issueswith innovative drugs: a European cohort study. Drug Saf. 2013Nov;36(11):1105-15.
  30. Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Stein P, Desai M,Shaw W, Jiang J, Vercruysse F, Meininger G, Matthews D. Rationale, design, andbaseline characteristics of the Canagliflozin Cardiovascular Assessment Study(CANVAS)--a randomized placebo-controlled trial. Am Heart J. 2013Aug;166(2):217-223.e11.
  31. Blood Pressure Lowering Treatment Trialists' Collaboration, Ninomiya T,Perkovic V, Turnbull F, Neal B, Barzi F, Cass A, Baigent C, Chalmers J, Li N,Woodward M, MacMahon S. Blood pressure lowering and major cardiovascular eventsin people with and without chronic kidney disease: meta-analysis of randomized controlled trials. BMJ. 2013 Oct 3;347:f5680.
  32. Nitsch D, Grams M, Sang Y, Black C, Cirillo M, Djurdjev O, Iseki K, JassalSK, Kimm H, Kronenberg F, Oien CM, Levey AS, Levin A, Woodward M, Hemmelgarn BR; Chronic Kidney Disease Prognosis Consortium. Associations of estimated glomerularfiltration rate and albuminuria with mortality and renal failure by sex: ameta-analysis. BMJ. 2013 Jan 29;346:f324.
  33. Piening S, de Graeff PA, Straus SM, Haaijer-Ruskamp FM, Mol PG. TheAdditional Value of an E-Mail to Inform Healthcare Professionals of a Drug SafetyIssue: A Randomized Controlled Trial in the Netherlands. Drug Saf. 2013 Jun 25.
  34. Reber KC, Piening S, Wieringa JE, Straus SM, Raine JM, de Graeff PA,Haaijer-Ruskamp FM, Mol PG. When direct health-care professional communicationshave an impact on inappropriate and unsafe use of medicines. ClinPharmacolTher.2013 Apr;93(4):360-5.
  35. Roman RJ, Van Dokkum RP. Commentary on the Special Issue on the Impact ofMyogenic tone in Health and Disease. CurrVascPharmacol. 2013 Sep 25.
  36. Samarska IV, Henning RH, Buikema H, Bouma HR, Houwertjes MC, Mungroop H,Struys MM, Absalom AR, Epema AH. Troubleshooting the rat model of cardiopulmonarybypass: effects of avoiding blood transfusion on long-term survival, inflammationand organ damage. J PharmacolToxicol Methods. 2013 Mar-Apr;67(2):82-90.
  37. Sandker SC, Mecozzi G, van Buiten A, Mariani MA, Buikema H, GrandjeanJG.Adventitial dissection: a simple and effective way to reduce radial artery spasm in coronary bypass surgery. InteractCardiovascThoracSurg. 2013Nov;17(5):784-9.
  38. Scheven L, Van der Velde M, Lambers Heerspink HJ, De Jong PE, Gansevoort RT. Isolated microalbuminuria indicates a poor medical prognosis. Nephrol DialTransplant. 2013 Jul;28(7):1794-801.
  39. Scheven L, Halbesma N, de Jong PE, de Zeeuw D, Bakker SJ, Gansevoort RT.Predictors of progression in albuminuria in the general population: results from the PREVEND cohort. PLoSOne. 2013 May 27;8(5):e61119.
  40. Schroten NF, Ruifrok WP, Kleijn L, Dokter MM, Silljé HH, Lambers HeerspinkHJ, Bakker SJ, Kema IP, van Gilst WH, van Veldhuisen DJ, Hillege HL, de Boer RA. Short-term vitamin D3 supplementation lowers plasma renin activity in patientswith stable chronic heart failure: an open-label, blinded end point, randomizedprospective trial (VitD-CHF trial). Am Heart J. 2013 Aug;166(2):357-364.e2.
  41. Sidorenkov G, Voorham J, Haaijer-Ruskamp FM, de Zeeuw D, Denig P. Associationbetween performance measures and glycemic control among patients with diabetes ina community-wide primary care cohort. Med Care. 2013 Feb;51(2):172-9.
  42. Sidorenkov G, Voorham J, de Zeeuw D, Haaijer-Ruskamp FM, Denig P. Treatmentquality indicators predict short-term outcomes in patients with diabetes: aprospective cohort study using the GIANTT database. BMJ QualSaf. 2013 Apr;22(4):339-47.23386729.
  43. Sidorenkov G, Voorham J, de Zeeuw D, Haaijer-Ruskamp FM, Denig P. Dotreatment quality indicators predict cardiovascular outcomes in patients withdiabetes? PLoSOne. 2013 Oct 30;8(10):e78821.
  44. Sinkeler SJ, Kwakernaak AJ, Bakker SJ, Shahinfar S, Esmatjes E, de Zeeuw D,Navis G, Lambers Heerspink HJ. Creatinine excretion rate and mortality in type 2 diabetes and nephropathy. Diabetes Care. 2013 Jun;36(6):1489-94.
  45. Talaei F, van Praag VM, Henning RH. Hydrogen sulfide restores a normalmorphological phenotype in Werner syndrome fibroblasts, attenuates oxidativedamage and modulates mTOR pathway. Pharmacol Res. 2013 Aug;74:34-44.
  46. Ulu N, Henning RH, Guner S, Zoto T, Duman-Dalkilic B, Duin M, Gurdal H.Intracellular transactivation of epidermal growth factor receptor byα1A-adrenoceptor is mediated by phosphatidylinositol 3-kinase independently ofactivation of extracellular signal regulated kinases 1/2 and serine-threonine
  47. kinases in Chinese hamster ovary cells. J PharmacolExpTher. 2013Oct;347(1):47-56.
  48. Ulu N, Mulder GM, Vavrinec P, Landheer SW, Duman-Dalkilic B, Gurdal H, Goris M, Duin M, van Dokkum RP, Buikema H, van Goor H, Henning RH. Epidermal growthfactor receptor inhibitor PKI-166 governs cardiovascular protection withoutbeneficial effects on the kidney in hypertensive 5/6 nephrectomized rats. JPharmacolExpTher. 2013 Jun;345(3):393-403.
  49. van der Graaf AM, Wiegman MJ, Plösch T, Zeeman GG, van Buiten A, Henning RH, Buikema H, Faas MM. Endothelium-dependent relaxation and angiotensin IIsensitivity in experimental preeclampsia. PLoS One. 2013 Nov 6;8(11):e79884.
  50. Vavrinec P, Henning RH, Landheer SW, Wang Y, Deelman LE, van Dokkum RP,Buikema H. Vildagliptin restores renal myogenic function and attenuates renalsclerosis independently of effects on blood glucose or proteinuria in ZuckerDiabetic Fatty rat. CurrVascPharmacol. 2013 Sep 25.
  51. Vavrinec P, Henning RH, Goris M, Landheer SW, Buikema H, van Dokkum RP. Renalmyogenic constriction protects the kidney from age-related hypertensive renaldamage in the Fawn-Hooded rat. J Hypertens. 2013 Aug;31(8):1637-45.
  52. Wirtz VJ, Mol PG, Verdijk J, Vander Stichele RH, Taxis K. Use ofantibacterial fixed-dose combinations in the private sector in eight LatinAmerican Countries between 1999 and 2009. Trop Med Int Health. 2013Apr;18(4):416-25.
  53. Özyilmaz A, Bakker SJ, de Zeeuw D, de Jong PE, Gansevoort RT; PREVEND StudyGroup. Screening for albuminuria with subsequent screening for hypertension andhypercholesterolaemia identifies subjects in whom treatment is warranted toprevent cardiovascular events. Nephrol Dial Transplant. 2013 Nov;28(11):2805-15.